EUVIMEDEUVIMED entdecken
Crossref

Using Genomic Heterogeneity to Inform Therapeutic Decisions for Metastatic Colorectal Cancer: An Application of the Value of Heterogeneity Framework

Reka E Pataky iD, Stuart Peacock iD, Stirling Bryan iD, Mohsen Sadatsafavi iD, Dean A Regier iD

Applied Health Economics and Health Policy · 2025

DOI: 10.1007/s40258-024-00926-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Applied Health Economics and Health Policy, 2025. Verfasst von Reka E Pataky und 4 weiteren Autor:innen. Beteiligte Einrichtung: Canadian Centre for Applied Research in Cancer Control, BC Cancer, Vancouver, BC, Canada. rpataky@bccrc.ca. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Genetic Heterogeneity. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Genome Canada, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Mutations in KRAS and NRAS are predictive of poor response to cetuximab and panitumumab, two anti-epidermal growth factor receptor (EGFR) monoclonal antibodies used in metastatic colorectal cancer (mCRC). Our objective was to explore the value of using KRAS and NRAS mutation status to inform third-line anti-EGFR therapy for mCRC using the value of heterogeneity (VOH) framework. METHODS: We used administrative data to identify mCRC patients who were potentially eligible for third-line therapy in 2006-2019 in British Columbia (BC), Canada. We compared three alternative stratification policies in place during the study period: the unstratified policy where anti-EGFR therapy was not offered (2006-2009), stratification by KRAS mutation (2009-2016), and stratification by KRAS+NRAS mutation (2016-2019). We used inverse-probability-of-treatment weighting to balance covariates across the three groups. Cost and survival time were calculated using a 3-year time horizon and adjusted for censoring, with bootstrapping to characterize uncertainty. Mean net monetary benefit (NMB) was calculated at a range of threshold values. The VOH of using KRAS and NRAS mutation status to inform treatment selection was calculated as the change in NMB with increasing stratification, under current (static VOH) or perfect (dynamic VOH) information. RESULTS: We included 2664 patients in the analysis. At a willingness-to-pay of CA$100,000/ life-year gained (LYG), stratification on KRAS mutation status provided a static VOH of CA$1565 per patient; further stratification on KRAS+NRAS provided additional static VOH of CA$594. The static VOH exceeded the marginal cost of genomic testing under both policies. CONCLUSIONS: Stratification of anti-EGFR therapy by KRAS and NRAS mutation status can provide additional value at a threshold of CA$100,000/LYG. There is diminishing marginal value and increasing marginal costs as the policy becomes more stratified. The VOH framework can illustrate the value of subgroup-specific decisions in a comprehensive way, to better inform targeted treatment policies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsGenetic HeterogeneityHumansFemaleMaleAgedGTP PhosphohydrolasesProto-Oncogene Proteins p21(ras)Membrane ProteinsMiddle AgedMutationBritish ColumbiaCetuximabPanitumumabErbB ReceptorsNeoplasm MetastasisCost-Benefit AnalysisClinical Decision-Making

Substanzen

GTP PhosphohydrolasesProto-Oncogene Proteins p21(ras)Membrane ProteinsNRAS protein, humanKRAS protein, humanCetuximabPanitumumabErbB Receptors

Autor:innen und Institutionen

  • Canadian Centre for Applied Research in Cancer Control, BC Cancer, Vancouver, BC, Canada. rpataky@bccrc.ca.
  • BC Cancer Research Centre, 675 W. 10th Ave, Vancouver, BC, V5Z 1L3, Canada. rpataky@bccrc.ca.
  • Canadian Centre for Applied Research in Cancer Control, BC Cancer, Vancouver, BC, Canada.
  • Faculty of Health Sciences, Simon Fraser University, Vancouver, BC, Canada.
  • Centre for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research Institute, Vancouver, BC, Canada.
  • School of Population and Public Health, The University of British Columbia, Vancouver, BC, Canada.

ORCID-Profile: Reka E Pataky, Stuart Peacock, Stirling Bryan, Mohsen Sadatsafavi, Dean A Regier

Förderung

  • Genome Canada
  • Canadian Institutes of Health Research

Zitieren

APA

Pataky, R. E., Peacock, S., Bryan, S., Sadatsafavi, M., & Regier, D. A. (2025). Using Genomic Heterogeneity to Inform Therapeutic Decisions for Metastatic Colorectal Cancer: An Application of the Value of Heterogeneity Framework. Applied Health Economics and Health Policy. https://doi.org/10.1007/s40258-024-00926-9

Vancouver

Pataky RE, Peacock S, Bryan S, Sadatsafavi M, Regier DA. Using Genomic Heterogeneity to Inform Therapeutic Decisions for Metastatic Colorectal Cancer: An Application of the Value of Heterogeneity Framework. Applied Health Economics and Health Policy. 2025. doi:10.1007/s40258-024-00926-9

BibTeX
@article{Pataky2025,
  author = {Pataky, Reka E and Peacock, Stuart and Bryan, Stirling and Sadatsafavi, Mohsen and Regier, Dean A},
  title = {Using Genomic Heterogeneity to Inform Therapeutic Decisions for Metastatic Colorectal Cancer: An Application of the Value of Heterogeneity Framework},
  journal = {Applied Health Economics and Health Policy},
  year = {2025},
  doi = {10.1007/s40258-024-00926-9}
}
Kostenlos starten →